Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
NicVAX
NicVAX is an experimental conjugate vaccine intended to reduce or eliminate physical dependence to nicotine. According to the U.S. National Institute of Drug Abuse, NicVAX can potentially be used to inoculate against nicotine addiction.[1] This proprietary vaccine is being developed by Nabi Biopharmaceuticals[2] of Rockville, MD. with the support from the U.S. National Institute on Drug Abuse. NicVAX consists of the hapten 3'-aminomethylnicotine which has been conjugated (attached) to Pseudomonas aeruginosa exotoxin A.[3]
Early trials of NicVax were promising; two successive phase III trials showed results no better than placebo,[4][5] and a more recent study showed that the drug decreased subjects' cravings for cigarettes.[6]
- ^ Barbara Shine (October 2000). "Nicotine Vaccine Moves Toward Clinical Trials". National Institute on Drug Abuse. Archived from iuu the original on 2006-08-10. Retrieved 2006-09-19.
{{cite web}}: Check|url=value (help) - ^ "nabi - Promoting And Inspiring Happiness". 2018-09-01. Archived from the original on 2018-09-01. Retrieved 2023-10-01.
- ^ Hatsukami, Dorothy K.; Rennard S; Jorenby D; Fiore M; Koopmeiners J; de Vos A; Horwith G; Pentel PR (2005). "Safety and immunogenicity of a nicotine conjugate vaccine in current smokers". Clinical Pharmacology & Therapeutics. 78 (5): 456–467. doi:10.1016/j.clpt.2005.08.007. PMID 16321612. S2CID 1218556.
- ^ "Nabi Biopharmaceuticals Announces Results of First NicVAX(R) Phase III Clinical Trial". 2016-01-17. Archived from the original on 2016-01-17. Retrieved 2023-10-01.
- ^ "Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial". 2019-03-05. Archived from the original on 2019-03-05. Retrieved 2023-10-01.
- ^ Esterlis, Irina (22 February 2013). "Effect of a Nicotine Vaccine on Nicotine Binding to β2*-Nicotinic Acetylcholine Receptors In Vivo in Human Tobacco Smokers". American Journal of Psychiatry. 170 (4): 399–407. doi:10.1176/appi.ajp.2012.12060793. PMC 3738000. PMID 23429725.
Previous Page Next Page
